Search results for "Dystrophy"

showing 10 items of 268 documents

Therapeutic use of hyaluronic acid fillers in the treatment of corticosteroid-induced skin and subcutaneous atrophy

2016

Corticosteroid injection–related tissue atrophy might cause permanent skin and soft tissue deformities1 due to several factors, most importantly fibroblast inhibition and decreased Type I collagen synthesis. Correction of these deformities is challenging and is mostly based on volume replacement with lipofilling or other methods. Clinical observations and research have shown that injection of stabilized hyaluronic acid (HA) induces collagen synthesis, partially restoring dermal matrix components, and eventually producing a permanent effect.2–5 Based on these data, we hypothesize that HA injections might successfully treat atrophic tissue changes caused by corticosteroid injection. We descri…

medicine.medical_specialtyDermal FillerEstheticsLipodystrophymedicine.drug_classInjections SubcutaneousSettore MED/19 - Chirurgia PlasticaBiocompatible MaterialsDermatologyCosmetic TechniquesAdrenal Cortex HormoneInjections SubcutaneouDermal Fillers030207 dermatology & venereal diseases03 medical and health scienceschemistry.chemical_compound0302 clinical medicineAtrophyIn vivoAdrenal Cortex HormonesDermal FillersHyaluronic acidmedicineHumansButtocksHyaluronic AcidBiocompatible MaterialCosmetic Techniquebusiness.industryGeneral MedicineMiddle Agedmedicine.diseaseDermatologymedicine.anatomical_structureCosmetic Techniqueschemistry030220 oncology & carcinogenesisCorticosteroidButtocksSurgeryFemaleLipodystrophyAtrophybusinessEstheticHuman
researchProduct

Secondary reduction in calpain 3 expression in patients with limb girdle muscular dystrophy type 2B and Miyoshi myopathy (primary dysferlinopathies).

2000

Made available in DSpace on 2016-10-10T03:52:18Z (GMT). No. of bitstreams: 5 Secondary reduction in calpain 3 expression in patients with limb girdle muscular dystrophy type 2B and Miyoshi myopathy.pdf: 167085 bytes, checksum: b445ec059ea2d0f06bd4fa913354872a (MD5) license_url: 52 bytes, checksum: 2f32edb9c19a57e928372a33fd08dba5 (MD5) license_text: 24259 bytes, checksum: f1f24f769b03eb8f9cd3f53c1090841c (MD5) license_rdf: 24658 bytes, checksum: 9d3847733d3c0b59c7c89a1d40d3d240 (MD5) license.txt: 1887 bytes, checksum: 445d1980f282ec865917de35a4c622f6 (MD5) Previous issue date: 2000 Dysferlin is the protein product of the gene (DYSF) that is defective in patients with limb girdle muscular dy…

medicine.medical_specialtyDysferlinopathyDNA Mutational AnalysisMuscle ProteinsMuscular DystrophiesWestern blottingDysferlinMuscular DiseasesLamininInternal medicinemedicineMissense mutationCalpain 3HumansMuscular dystrophyDysferlinGenetics (clinical)Geneticsbiologybusiness.industryCalpainMembrane ProteinsCalpainmedicine.diseaseMuscular dystrophyLaminin alpha 2EndocrinologyMuscle proteinsNeurologyPediatrics Perinatology and Child Healthbiology.proteinNeurology (clinical)LamininbusinessMerosinLimb-girdle muscular dystrophyNeuromuscular disorders : NMD
researchProduct

Efavirenz induces alterations in lipid metabolism through AMPK activation

2008

Summary of results EFV produced an immediate reduction of mitochondrialfunction, evident by the significant and dose-dependentinhibition of mitochondrial O2 consumption and thedecrease of intracellular ATP and Δψm. This metabolicstress promoted the activation of AMPK, triggering severalof its signalling pathways, as EFV induced an increment inCD36 mRNA expression and in intracellular lipid content,which could have been a result of the formation of lipiddroplets. This intracellular lipid increase was not presentin cells treated with Compound C, which points to a keyrole for AMPK in these mechanisms. Conclusion Given that EFV treatment is usually prolonged, thesemechanisms may effect the gene…

medicine.medical_specialtyEfavirenzbusiness.industryPublic Health Environmental and Occupational HealthAMPKLipid metabolismmedicine.diseasechemistry.chemical_compoundInfectious DiseasesEndocrinologychemistryInternal medicinemedicineLipodystrophybusinessProtein kinase ALipoatrophyIntracellularCompound cJournal of the International AIDS Society
researchProduct

Insulin Resistance and the Cardiometabolic Syndrome in HIV Infection

2009

Highly active antiretroviral therapy (HAART) has dramatically improved the prognosis of HIV-positive patients. However, long-term adverse effects of this therapy include dyslipidemia, insulin resistance (IR), changes in body fat distribution (lipodystrophy), and cardiometabolic syndrome (CMS). IR in HIV-positive patients does not seem to represent a significant independent risk factor for the development of cardiovascular disease; nevertheless, the association with other metabolic complications (dyslipidemia, fat redistribution) and CMS may increase the risk of type 2 diabetes and cardiovascular disease. The use of nucleoside analogue reverse transcriptase inhibitors is associated with the …

medicine.medical_specialtyEndocrinology Diabetes and MetabolismHIV InfectionsType 2 diabetesGastroenterologyInsulin resistanceAntiretroviral Therapy Highly ActiveDiabetes mellitusInternal medicineInternal MedicinemedicineHumansRisk factorMetabolic Syndromebusiness.industrymedicine.diseaseMetforminEndocrinologyCardiovascular DiseasesInsulin ResistanceLipodystrophyCardiology and Cardiovascular MedicinebusinessRosiglitazoneDyslipidemiamedicine.drugJournal of the CardioMetabolic Syndrome
researchProduct

Multifocal disseminated lipoatrophy secondary to intravenous corticosteroid administration in a patient with adrenal insufficiency.

2002

Multifocal disseminated lesions of circumscribed lipoatrophy have not been described as an adverse reaction of intravenously applied drugs. A unique patient with adrenal insufficiency is reported who received corticosteroids intravenously and then had multiple lesions develop that were similar to focal lipoatrophy as known to occur secondary to faulty intradermal injections of corticosteroids.

medicine.medical_specialtyLipodystrophymedicine.drug_classbusiness.industryPrednisoloneDermatologyMiddle Agedmedicine.diseaseRisk AssessmentSeverity of Illness IndexSurgeryToxicitymedicineAdrenal insufficiencyCorticosteroidHumansFemalebusinessAdverse effectInfusions IntravenousLipoatrophyAdrenal InsufficiencyFollow-Up StudiesJournal of the American Academy of Dermatology
researchProduct

Bilateral Ultrathin Descemet’s Stripping Automated Endothelial Keratoplasty vs. Bilateral Penetrating Keratoplasty in Fuchs’ Dystrophy: Corneal Highe…

2021

Background and Objectives: The objective of this paper is to compare the visual outcomes and quality of life (QoL) after bilateral ultrathin Descemet’s stripping automated endothelial keratoplasty (UT-DSAEK) with bilateral penetrating keratoplasty (PK) for Fuchs’ endothelial dystrophy (FED). Materials and Methods: Retrospective comparative cohort study, including 11 patients with FED who underwent bilateral PK and 13 patients with FED who underwent bilateral UT-DSAEK. All patients were already pseudophakic or had undergone a combined cataract procedure. The main outcomes were corrected distance visual acuity (CDVA) corneal higher-order aberrations (HOAs), contrast sensitivity (CS) and quali…

medicine.medical_specialtyMedicine (General)Visual acuityDistance visual acuitygenetic structuresvisual acuitymedia_common.quotation_subjectmedicine.medical_treatmentFuchs' dystrophyArticleCohort StudiesR5-920Quality of lifeOphthalmologyhigher-order aberrationmedicineContrast (vision)HumansEye surgerymedia_commonRetrospective Studiescontrast sensitivityhigher-order aberrationsbusiness.industryFuchs' Endothelial DystrophyDystrophybilateral penetrating keratoplastyGeneral Medicinemedicine.diseasebilateral ultrathin DSAEKeye diseasesAberrations of the eyebilateral ultrathin DSAEK; bilateral penetrating keratoplasty; visual acuity; contrast sensitivity; higher-order aberrations; quality of lifequality of lifevisual acuity.medicine.symptombusinessDescemet Stripping Endothelial KeratoplastyKeratoplasty PenetratingMedicina
researchProduct

Muscle pathology in 57 patients with myotonic dystrophy type 2

2004

We evaluated muscle biopsies from 57 patients with genetically confirmed myotonic dystrophy type 2/proximal myotonic myopathy (DM2/PROMM). Light microscopy showed myopathic together with “denervation-like” changes in almost all biopsies obtained from four different muscles: increased fiber size variation, internal nuclei, small angulated fibers, pyknotic nuclear clumps, and predominant type 2 fiber atrophy. Quantitative morphometry in 18 biopsies that were immunostained for myosin heavy chain confirmed a predominance of nonselective type 2 fiber atrophy. These histological changes were similar in all patients regardless of the site of biopsy, the predominant clinical symptoms and signs, and…

medicine.medical_specialtyPathologyMuscle biopsymedicine.diagnostic_testPhysiologybusiness.industryAnatomical pathologymedicine.diseaseMyotoniaMyotonic dystrophyProximal myotonic myopathyCellular and Molecular NeuroscienceAtrophyPhysiology (medical)BiopsymedicineHistopathologyNeurology (clinical)businessMuscle & Nerve
researchProduct

Deflazacort in Duchenne dystrophy: Study of long-term effect

1994

A randomized double-blind controlled trial of deflazacort was conducted in 28 Duchenne muscular dystrophy patients either treated with deflazacort 2.0 mg/kg alternate-day therapy or placebo. The deflazacort group showed significant improvement in climbing stairs (P < 0.01), in rising from a chair, Gower's maneuver, and walking (P < 0.0025) after 6 months of treatment. After 1 year, all the above changes remained significantly improved and the MRC index was significantly better (P < 0.05) in the treated group. After 2 years, a significant change was found in the MRC index: higher scores in walking, chair rising (P < 0.02), and grade and time of Gower's maneuver (P < 0.05) were found. The mea…

medicine.medical_specialtyPatient DropoutsTime Factorsmedicine.drug_classPhysiologyDuchenne muscular dystrophymedicine.medical_treatmentMotor ActivityPlaceboMuscular Dystrophieslaw.inventionCellular and Molecular NeuroscienceDouble-Blind MethodRandomized controlled trialPregnenedioneslawPhysiology (medical)medicineHumansChildGaitChemotherapybusiness.industryMusclesAnti-Inflammatory Agents Non-SteroidalBody Weightmedicine.diseaseSurgeryClinical trialDeflazacortAnesthesiaCorticosteroidNeurology (clinical)medicine.symptombusinessWeight gainFollow-Up Studiesmedicine.drugMuscle &amp; Nerve
researchProduct

Elevated plasma levels of cardiac troponin-I predict left ventricular systolic dysfunction in patients with myotonic dystrophy type 1: A multicentre …

2017

Objective:\ud \ud High sensitivity plasma cardiac troponin-I (cTnI) is emerging as a strong predictor of cardiac events in a variety of settings. We have explored its utility in patients with myotonic dystrophy type 1 (DM1).\ud Methods:\ud \ud 117 patients with DM1 were recruited from routine outpatient clinics across three health boards. A single measurement of cTnI was made using the ARCHITECT STAT Troponin I assay. Demographic, ECG, echocardiographic and other clinical data were obtained from electronic medical records. Follow up was for a mean of 23 months.\ud Results:\ud \ud Fifty five females and 62 males (mean age 47.7 years) were included. Complete data were available for ECG in 107…

medicine.medical_specialtySciencePopulationmacromolecular substances030204 cardiovascular system & hematologyMyotonic dystrophy03 medical and health sciences0302 clinical medicineInternal medicineTroponin IJournal ArticleMedicineOutpatient cliniccardiovascular diseaseseducationeducation.field_of_studyMultidisciplinarymedicine.diagnostic_testbiologybusiness.industryQRmedicine.diseaseTroponinSurgeryCohortAmbulatoryCardiologybiology.proteincardiovascular systemMedicinebusinessElectrocardiography030217 neurology & neurosurgeryPLoS ONE
researchProduct

Increased susceptibility to lipid peroxidation in skeletal muscles of dystrophic hamsters.

1989

The results showed that the total content of lipids, which could be peroxidized with Fe(2 +)/ascorbate stimulation in vitro, was 45.4% and 53.7% higher than normal in the dystrophic hamster muscle at the age of 1 and 3 months, respectively. Correspondingly, the susceptibility to lipid peroxidation (stimulated by ADP-chelated iron at 37 degrees C) was 38.6-74.3% higher in dystrophic muscles. The increases were not related to necrotic lesions and inflammation observed. The activities of glucose-6-phosphate dehydrogenase, glutathione reductase, thioredoxin reductase and catalase were increased in dystrophic muscles but those of superoxide dismutases and glutathione peroxidase were unaffected.

medicine.medical_specialtyThioredoxin-Disulfide ReductaseThioredoxin reductaseGlutathione reductaseHamsterStimulationGlucosephosphate DehydrogenaseAntioxidantsLipid peroxidationSuperoxide dismutaseCellular and Molecular Neurosciencechemistry.chemical_compoundInternal medicineCricetinaemedicineAnimalsMolecular BiologyCreatine KinasePharmacologychemistry.chemical_classificationGlutathione PeroxidasebiologySuperoxide DismutaseGlutathione peroxidaseMusclesCell BiologyMuscular Dystrophy AnimalMolecular biologyEndocrinologyGlutathione ReductasechemistryCatalasebiology.proteinMolecular MedicineLipid PeroxidationExperientia
researchProduct